Harbour BioMed develops antibody therapeutics in oncology and immunology areas. Credit: Harbour BioMed.

Developed from Harbour Mice, HBM4003 is a human monoclonal heavy chain only antibody that acts against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).

The drug is said to exhibit antibody-dependent cell cytotoxicity (ADCC) killing and is selective to high CTLA-4 Treg cells present in tumour tissues. Its mechanism of action is expected to improve efficacy and lower drug toxicity.

HBM4003 is undergoing an open label, multi-centre global trial to treat advanced solid tumours.

Part 1 of the Phase I was a dose escalation study, and Phase Ib/IIa trial will progress to dose expansion to further analyse the drug’s anti-tumour activities in various solid tumours.

In the part 2 of Phase I, Australians suffering from metastatic or advanced melanoma, hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) and other tumours will be recruited.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study is assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumour activity of HBM4003 as a monotherapy. It will also identify the maximum tolerated dose and/or recommended Phase II dose.

Harbour BioMed submitted results from Phase I part 1 to European Society of Medical Oncology (ESMO). The trial is expected to complete in February next year.

Harbour BioMed founder, chairman and CEO Dr Jingsong Wang said: “HBM4003 has shown strong anti-tumour activity and great safety in its Phase I clinical studies.

“We will continue to accelerate the global development of HBM4003 for multiple tumour types, so that we can help cancer patients around the world to live better and longer lives.”

Last year, Harbour BioMed received the US Food and Drug Administration (FDA) approval to conduct a Phase II clinical trial of HBM9167 to treat nasopharyngeal cancer (NPC).